Panel: Viral vectors (Lenti, Retro, AAV, & gene transfer) Vs. their non-viral alternatives
Getting technical - Cell & Gene Therapy Europe
- A one hour debate which includes a case study from each side - audience questions and involvement is encouraged.
- Would non-viral vector approaches and DNA approaches get us past the challenges we are encountering with viral vectors? COGs, re-dosing, quality for GMP supply at commercial scale- surviving the regulators, capacity etc.
- Can we get good enough gene integration to shorten the process? Can we transfect/transduce and go straight into the patient without the need to expand cells to greatly reduce time and cost, risk of contamination, cell exhaustion etc.